Insys Therapeutics aims to take the rough edges off of chemo and cancer pain. The drug development company is focused on treating side effects of chemotherapy, as well as therapies for pain management. Its lead candidate is a fast-acting oral spray version of cancer pain drug Fentanyl. Its Dronabinol candidate is a generic capsule form of Marinol (a synthetic version of the active chemical in marijuana) for treatment of chemotherapy-induced nausea and vomiting. Both drugs are in late stage development awaiting FDA approval. All of the company's drug candidates are re-formulations of already-approved therapeutic ingredients. Insys filed to go public in 2011.